HC Wainwright Cuts Earnings Estimates for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities research analysts at HC Wainwright decreased their FY2027 earnings per share estimates for shares of Kodiak Sciences in a research report issued to clients and investors on Monday, September 28th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($3.36) per share for the year, down from their prior estimate of ($3.27). HC Wainwright has a “Buy” rating and a $96.00 price objective on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.89) per share. HC Wainwright also issued estimates for Kodiak Sciences’ FY2028 earnings at ($1.78) EPS, FY2029 earnings at $1.76 EPS and FY2030 earnings at $5.81 EPS.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09).

Several other research firms have also recently commented on KOD. UBS Group boosted their target price on Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Kodiak Sciences in a research report on Friday, July 10th. Lifesci Capital increased their target price on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a report on Monday. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $103.00 target price on shares of Kodiak Sciences in a research report on Wednesday. Finally, Wall Street Zen lowered shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.43.

Kodiak Sciences Stock Performance

NASDAQ:KOD opened at $91.12 on Wednesday. The company has a market cap of $5.73 billion, a PE ratio of -21.75 and a beta of 2.18. Kodiak Sciences has a 52-week low of $10.94 and a 52-week high of $95.77. The stock has a 50-day simple moving average of $40.26 and a 200 day simple moving average of $38.27.

Hedge Funds Weigh In On Kodiak Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Arizona State Retirement System boosted its holdings in shares of Kodiak Sciences by 6.9% during the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after buying an additional 554 shares during the period. V Square Quantitative Management LLC bought a new stake in shares of Kodiak Sciences during the first quarter worth approximately $26,000. Westfuller Advisors LLC bought a new position in shares of Kodiak Sciences during the first quarter worth approximately $26,000. EverSource Wealth Advisors LLC lifted its holdings in Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after purchasing an additional 916 shares during the last quarter. Finally, KBC Group NV bought a new stake in Kodiak Sciences in the 1st quarter valued at $39,000. 89.06% of the stock is owned by institutional investors.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Phase 3 success supports potential approval: Zenkuda and tabirafusp-ted (KSI-501) met their primary endpoints in the DAYBREAK study, with results indicating efficacy comparable to Regeneron’s established Eylea. Kodiak plans to advance Zenkuda toward a biologics license application (BLA), moving the drug closer to commercialization. KOD Stock Soars on Positive Wet AMD Data
• Positive Sentiment: Analysts raised price targets: Lifesci Capital increased its target from $85 to $145 and retained an outperform rating. UBS raised its target from $80 to $120 with a buy rating, while HC Wainwright lifted its target from $58 to $96 and also maintained a buy rating. The revisions reflect greater confidence in Kodiak’s regulatory and commercial prospects. Lifesci Capital Raises Price Target
• Positive Sentiment: Large addressable market: Coverage highlighted the potential opportunity in retinal drugs, a market expected to exceed $32 billion by the end of the decade. A longer-acting treatment that can compete with Eylea could offer meaningful commercial upside if approved. Why Kodiak Sciences Skyrocketed

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.